Pulmonary arterial hypertension among Filipino patients with connective tissue diseases

References

• Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hyper-tension. N Engl J Med. 1992;327(2):70–5.
   Google Scholar
• Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732–9.
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patient with pulmonary hypertension. N Engl J Med 1995;333:214–21.
   PubMed Web of Science ®Google Scholar
• Rich S, editor. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998, Evian, France, September 6–10, 1998, co-sponsored by the World Health Organization; 1998.
   Google Scholar
• Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension. Chest 2004;126:35S–62S.
   Google Scholar
• Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002;19:571–6.
   PubMedGoogle Scholar
• Lim MC, Navarra SV, Tan-Ong MY. Clinical presentation and disease course of pulmonary hypertension among Filipinos with systemic lupus erythematosus. Philipp J Intern Med 2002;40: 140–3.
   Google Scholar
• Klippel JH, Crofford LJ, Stone JH, Weyand CM. Primer on the rheumatic diseases. 12th ed. Arthritis Foundation, Atlanta, Georgia 2001.
   Google Scholar
• Simmoneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hyper-tension. J Am Coll Cardiol 2004;43 Suppl 12:5S–12S.
   Google Scholar
• Harris EN, Khamashta MA. Antiphospholipid syndrome. Ftheu-matology. 3rd ed. Mosby 2003.
   Google Scholar
• Levine JS. The antiphospholipid syndrome. N Engl J Med 2002;346 (10):752–63.
   PubMed Web of Science ®Google Scholar
• Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Ftheumatol 1996;35: 989–93.
   Google Scholar
• Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, et al. Exhaled nitric oxide in systemic sclerosis: rela-tionships with lung involvement and pulmonary hypertension. J Ftheumatol 2000;27:1693–8.
   Google Scholar
• Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515–9.
   PubMed Web of Science ®Google Scholar
• Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evalu-ation of pulmonary arterial hypertension in patients with progres-sive systemic sclerosis and related syndromes. Jpn Circ J 1992;56: 983–91.
   PubMedGoogle Scholar
• Yamane K, Ihn H, Asano Y, Yazawa N, Kubo M, Kikuchi K, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Ftheumatology (Oxford) 2000;39: 1269–71.
   PubMed Web of Science ®Google Scholar
• Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42:899–909.
   PubMed Web of Science ®Google Scholar
• Hinderliter AL, Willis PW IV, Barst RJ, Rich S, Rubin LJ, Badesch DB. Effects of long term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: primary pulmonary hypertension study group. Circulation 1997;95:1479–86.
   PubMed Web of Science ®Google Scholar
• Shen JY, Chen SL, Wu IX, Tao RQ, Gu YY, Bao CD, et al. Pul-monary hypertension in systemic lupus erythematosus. Ftheumatol Int 1999;18:147–51.
   PubMed Web of Science ®Google Scholar
• Winslow TM, Ossipov MA, Fazio GP, Foster E, Simonson JS, Schiller NB, et al. The left ventricle in systemic lupus erythemato-sus: initial observation and a five-year follow-up in a university medical center population. Am Heart J 1993;125:1117–22.
   PubMedGoogle Scholar
• Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythema-tosus: evaluation of clinical characteristics and response to immu-nosuppressive treatment. J Ftheumatol 2002;29:282–7.
   Google Scholar
• Medsger TA, Shur PH. The clinical management of systemic lupus erythematosus. 2nd ed. New York: Lippincott-Raven; 1996. p. 89.
   Google Scholar
• Wallace DJ, Hahn HB. Dubois' lupus erythematosis. 5th ed. Mary-land: Williams and Wilkins; 1997. p. 682–4.
   Google Scholar
• McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest 2004:126 Supp1:145–345.
   Google Scholar
• McCrory DC. Methodology and grading for pulmonary hyperten-sion evidence review and guideline development. Chest 2004;126: 11S–13S.
   Google Scholar
• Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hyperten-sion. N Engl J Med 1992;327:70–5.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925–32.
   PubMed Web of Science ®Google Scholar
• MacLean MR. Endothelin-1: a mediator of pulmonary hyperten-sion? Pulm Pharmacol Ther 1998;11:125–32.
   PubMedGoogle Scholar
• Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353: 133–8.
   PubMed Web of Science ®Google Scholar